Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

BillionToOne, Inc.

NASDAQ: BLLN · Industrial Applications and Services · 13 alerts · CIK 2070849

Share price
$96.31Close, Nov 16
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All BillionToOne, Inc. filings on SEC EDGAR ↗

8:43 PM ET Form 4
Insider Selling

BillionToOne SVP of Laboratory Operations Bosch John Roderick ten Sells $321K of Stock

Bosch John Roderick ten, SVP of Laboratory Operations, sold 2,834 shares of BillionToOne, Inc. at $113.17 a share, worth $321K in total on Nov 2, 2026. Shares held after the trade: 16,551 (-7.9%).

Value
$321K
Shares
2,834
Average price
$113.17
Role
SVP of Laboratory Operations
Holding change
-7.9%
Trade date
Nov 2, 2026
8:43 PM ET Form 4
Insider Selling

BillionToOne Chairman and CEO Oguzhan Atay Sells $3.33M of Stock

Oguzhan Atay, Chairman and CEO, sold 30,335 shares of BillionToOne, Inc. at $107.31 to $113.17 a share (average $109.93) in 14 transactions, worth $3.33M in total on Nov 2, 2026. Shares held after the trade: 141,167 (-1.9%).

Value
$3.33M
Shares
30,335
Average price
$109.93
Role
Chairman and CEO
Holding change
-1.9%
Trade date
Nov 2, 2026
8:42 PM ET Form 4
Insider Selling

BillionToOne CTO David Tsao Sells $2.18M of Stock

David Tsao, CTO, sold 19,977 shares of BillionToOne, Inc. at $107.31 to $113.17 a share (average $109.24) in 13 transactions, worth $2.18M in total on Nov 2, 2026. Shares held after the trade: 1,023 (-16.9%).

Value
$2.18M
Shares
19,977
Average price
$109.24
Role
CTO
Holding change
-16.9%
Trade date
Nov 2, 2026
4:48 PM ET 10-Q
Financial Results

BillionToOne Q3 2026 Results: Net Income $17.4M, Up 204.5% YoY

BillionToOne, Inc. reported significant growth for the nine months ended September 30, 2026, with revenue increasing to $340.8 million from $209.1 million in the prior year. The company achieved a net income of $43.4 million for the first nine months of 2026, a substantial improvement compared to $1.5 million in the same period of 2025.

Key figure
Net income $17.4M · +204.5% YoY
4:21 PM ET 8-K
Financial Results

BillionToOne Financial Results

BillionToOne reported Q3 2026 revenue of $123.0 million, a 47% increase year-over-year, driven by strong growth in both prenatal and oncology clinical testing. The company maintained GAAP profitability with $11.0 million in operating income and raised its full-year 2026 revenue guidance to a range of $460 million to $470 million.

Term
Q3 2026

“Our third quarter was another period of strong execution. We delivered rapid growth with continued GAAP profitability, and more clinicians are choosing our tests in both prenatal and oncology.”

Dr. Oguzhan Atay, Co-Founder and CEO
6:54 PM ET Form 4
Insider Selling

BillionToOne Chairman and CEO Oguzhan Atay Sells $1.3M of Stock

Oguzhan Atay, Chairman and CEO, sold 11,000 shares of BillionToOne, Inc. at $118.00 a share, worth $1.3M in total on Oct 28, 2026. Shares held after the trade: 146,501 (-1.8%).

Value
$1.3M
Shares
11,000
Average price
$118.00
Role
Chairman and CEO
Holding change
-1.8%
Trade date
Oct 28, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.